The Krebs cycle is of fundamental importance for the generation of the energetic and molecular needs of both prokaryotic and eukaryotic cells. Both enantiomers of metabolite 2-hydroxyglutarate are directly linked to this pivotal biochemical pathway and are found elevated not only in several cancers, but also in different variants of the neurometabolic disease 2-hydroxyglutaric aciduria. Recently we showed that cancer-associated IDH2 germline mutations cause one variant of 2-hydroxyglutaric aciduria. Complementary to these findings, we now report recessive mutations in SLC25A1, the mitochondrial citrate carrier, in 12 out of 12 individuals with combined D-2-and L-2-hydroxyglutaric aciduria. Impaired mitochondrial citrate efflux, demonstrated by stable isotope labeling experiments and the absence of SLC25A1 in fibroblasts harboring certain mutations, suggest that SLC25A1 deficiency is pathogenic. Our results identify defects in SLC25A1 as a cause of combined D-2-and L-2-hydroxyglutaric aciduria. cause of combined D,L-2-HGA could therefore not only improve our knowledge of the pathophysiology of this neurometabolic disorder, but also provide further insight into its role in cancer. We performed whole-exome sequencing to identify the genetic basis of combined D,L-2-HGA in DNA of three affected individuals and the unaffected parents of one of them (subject 1). A total of 13 affected individuals
. Manifestations of both types of D-2-HGA include developmental delay, hypotonia, and seizures. 2 Recessive mutations in L2HGDH result in L-2-hydroxyglutaric aciduria 8, 9 (L-2-HGA [MIM 236792]), and predominant signs include macrocephaly, developmental delay, epilepsy, and cerebellar ataxia. Combined D-2-and L-2-hydroxyglutaric aciduria (D,L-2-HGA), characterized by elevated levels of both D-2-HG and L-2-HG in body fluids, is not caused by mutations in any of the abovementioned genes and mainly manifests in a severe neonatal epileptic encephalopathy, absence of developmental progress, and often early death 10 (Table S1 available online).
Elevated D-2-HG levels are also found in gliomas and myeloid leukemias 3, 11 and are associated with recurrent mutations in the isocitrate dehydrogenase (IDH) genes IDH1 or IDH2. These mutations disable the normal ability of IDH to convert isocitrate to a-ketoglutarate and result in a new function: converting a-ketoglutarate to D-2-HG. 3 However, elevated D-2-HG and L-2-HG levels are also found in thyroid carcinomas without IDH mutations, 4 caused by still unknown mechanisms. The exact role of ''oncometabolite'' 2-hydroxyglutarate (2-HG) in cancer is not yet fully understood, but recent studies indicate an important role in epigenetics. [12] [13] [14] Identifying the genetic cause of combined D,L-2-HGA could therefore not only improve our knowledge of the pathophysiology of this neurometabolic disorder, but also provide further insight into its role in cancer. We performed whole-exome sequencing to identify the genetic basis of combined D,L-2-HGA in DNA of three affected individuals and the unaffected parents of one of them (subject 1). A total of 13 affected individuals diagnosed with combined D,L-2-HGA from 12 unrelated families (Arabic, European, or Latin-American descent) were included in this study. They all showed elevated levels of D-2-HG and L-2-HG in urine (Table S2) that were homozygous (100% of the reads) in the affected individual and heterozygous (50% of the reads) in either parent with >403 coverage depth. Of these three genes, only SNVs in SLC25A1, with the above-mentioned criteria, were identified in the other two affected individuals (subjects 2 and 3). A similar search for small insertions or deletions did not identify any additional genes. Sanger sequencing of the ORF of SLC25A1 confirmed the mutations in these three individuals and their families and revealed mutations in nine additional unrelated affected subjects (Table 1 ). In total, 12 different mutations were detected ( Figure 1A ): eight missense, one nonsense, two frameshift (of which one was recurrent in four unrelated individuals), and one mutation resulting in a splicing error. The latter mutation, c.821C>T, found in three unrelated individuals, is located at the most 3 0 end of exon 8 and introduces a splice donor site, resulting in a deletion in mRNA (r.820_821del), and is predicted to cause a frameshift at the protein level (p.Ala274Ilefs*24). Sequencing of mRNA from fibroblasts derived from subject 4 confirmed a 2 bp deletion ( Figure S2 ). All missense mutations were predicted with SIFT to be damaging (Table 1) .
With immunoblot analysis, we examined SLC25A1 in fibroblasts available from seven affected individuals ( Figures  1B and S3 ). SLC25A1 was detected in cells from control subjects and all subjects harboring homozygous or compound heterozygous missense mutations. However, in cells from subjects containing two alleles with truncating mutations (subjects 7 and 9), no protein was detected, probably as a consequence of nonsense-mediated decay. The homozygous splice site mutation c.821C>T (subject 4; p.Ala274Ilefs*24) had reduced levels of SLC25A1. This could be explained by some authentic spliced protein product (p.Ala274Val), or alternatively, because the frameshift occurs at the C-terminal end, this protein could still be immunodetected but is degraded at higher rate.
The location of SLC25A1 within the human genome was previously described to be involved in other disorders.
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SLC25A1 is located on chromosome 22q11 within the critical region deleted in DiGeorge syndrome 20 (MIM 188400).
DiGeorge syndrome is a rather common congenital disorder (prevalence of 1:4,000) caused by a hemizygous deletion of chromosome 22q11.2 (containing~45 genes), with a wide variety of clinical abnormalities including heart defects, velopharyngeal inadequacies, recurrent infections, and learning disabilities. 21 Consequently, individuals with DiGeorge syndrome are heterozygous carriers of SLC25A1 deficiency. Expression of SLC25A1 mRNA is high in liver, kidney, and pancreas. 22 It encodes a protein of 311 amino acids containing six transmembrane helices that is located in the inner mitochondrial membrane. SLC25A1 mediates the efflux of mitochondrial citrate or isocitrate in exchange for cytosolic malate. 23 Citrate and isocitrate are intermediates of the Krebs cycle, which occurs in the matrix of mitochondria and is responsible for energy production. Citrate exported by SLC25A1 out of the mitochondria into the cytosol is converted into acetyl coenzyme A (acetyl-CoA), which is essential for fatty acid and sterol synthesis. 24 Furthermore, cytosolic citrate is an important regulator of glycolysis, because it is an allosteric inhibitor of 6-phosphofructokinase (PFK1), the most important regulator enzyme of glycolysis. 24 To examine the effect of SLC25A1 deficiency, we retrospectively measured the urinary citrate and isocitrate levels of individuals with combined D,L-2-HGA by using liquid chromatography-tandem mass spectrometry. Compared to age-matched controls (n ¼ 40), significantly lower levels of both metabolites were detected (Figures 2A and 2B ; Table S2 ). Interestingly, the eldest affected individual (subject 10) in our cohort showed the highest levels of citrate and isocitrate (Table S2) . To further study SLC25A1 activity, we incubated combined D,L-2-HGA-affected fibroblasts (n ¼ 7) and controls (n ¼ 2) with [U- 13 Figure 2C ; Table S2 ). This demonstrates that SLC25A1 mutations result in impaired citrate efflux. Interestingly, fibroblasts from subject 7 (c.18_24dup and c.768C>G) and subject 9 (c.18_24dup) showed~7% efflux as compared to controls, indicating that citrate can leave to a lesser extent the mitochondrial matrix via other means than SLC25A1 or is formed in the cytosol. Individuals with combined D,L-2-HGA excrete increased levels of several Krebs cycle intermediates including a-ketoglutarate, malate, fumarate, and succinate, accompanied with decreased levels of citrate and isocitrate (Table  S2) . We speculate that the increased urinary excretion of D-2-HG and L-2-HG is caused by the inability of mitochondria to export citrate and isocitrate into the cytosol. This would probably result in increased mitochondrial concentrations, and subsequently higher excretion, of Krebs cycle metabolites downstream of isocitrate. We therefore measured the above-mentioned metabolites in homogenates of fibroblasts from controls and affected individuals (Table S4) . Compared to controls, the levels of D-2-HG and L-2-HG in affected individuals are increased, which is in agreement with previously reported data. 25 Additionally, citrate levels were lower in affected fibroblasts, but isocitrate and the other metabolites were normal compared to controls.
In conclusion, SLC25A1 mutations cause combined D,L-2-HGA as well as altered levels of several Krebs cycle intermediates. This finding provides the basis for an understanding of the pathophysiology and future therapeutic research concerning this disease that may include citrate supplementation. SLC25A1 deficiency may be underdiagnosed and inclusion in the differential diagnosis of mitochondrial disorders should be considered. Further research is needed to unravel how SLC25A1 defects cause elevation of 2-HG, a cancer-associated metabolite. Although no cancer was diagnosed in our combined D,L-2HGA cohort (Table S1) , an important role for citrate or SLC25A1 has previously been implied in epigenetics or cancer biology. [26] [27] [28] [29] [30] The absence of cancer cases in our combined D,L-2-HGA cohort might be explained by the early age of death. Another explanation might be that the L-2-HG levels in our cohort are not as high as in L-2-HGA-affected individuals. Only L-2-HGA has previously been associated with higher incidences of cancer. 5 In both types of D-2-HGA, no higher incidence of cancer has been found. 2 Moreover, certain cancer types show elevated levels of 2-HG but contain no mutations in IDH1 or IDH2. 4 It would therefore be interesting to further investigate the role of citrate and SLC25A1 in these cancer types.
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